伟思医疗 (688580.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	472.9M	462.7M	400.1M	462.2M	321.6M
Cost of Revenue	160.4M	156.5M	138.2M	149.2M	88.5M
Gross Profit	312.5M	306.3M	261.8M	313.1M	233.1M
Operating Expenses
R&D Expense	46.2M	45.1M	50.6M	57.7M	43.7M
SG&A Expense	—	—	—	—	—
General & Admin Expense	48.6M	47.4M	44.5M	47.5M	38.2M
Selling & Marketing Expense	92.6M	91.8M	94.4M	105.0M	91.5M
Other Expenses	—	—	—	—	—
Total Operating Expenses	192.4M	188.0M	186.6M	197.9M	158.5M
Cost and Expenses	352.7M	344.5M	324.8M	347.0M	247.0M
Operating Income (EBIT)	185.6M	152.3M	111.5M	148.4M	104.5M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	187.8M	154.4M	113.3M	150.0M	105.8M
Income Tax Expense	21.3M	16.4M	11.3M	13.8M	12.0M
Bottom Line
Net Income	166.4M	138.1M	102.0M	136.3M	93.8M
Earnings from Cont. Ops	166.4M	138.1M	102.0M	136.3M	93.8M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	166.4M	138.1M	102.0M	136.3M	93.8M
Per Share
Basic EPS	CN¥1.73	CN¥1.44	CN¥1.07	CN¥1.43	CN¥1.37
Diluted EPS	CN¥1.73	CN¥1.44	CN¥1.07	CN¥1.42	CN¥1.37
Revenue Per Share	CN¥4.91	CN¥4.83	CN¥4.20	CN¥4.84	CN¥4.71
Shares
Basic Shares Outstanding	96.2M	95.9M	95.3M	95.6M	68.3M
Diluted Shares Outstanding	96.2M	95.9M	95.3M	95.6M	68.3M
Profitability Metrics
EBITDA	—	180.2M	133.7M	169.2M	122.1M
D&A	—	27.9M	22.2M	20.8M	17.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026